790
Participants
Start Date
March 29, 2017
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2028
Prednisone
Given orally (PO).
Vincristine
Given intravenously (IV).
Daunorubicin
Given IV.
Pegaspargase
Given IV or intramuscularly (IM) .
Erwinase®
To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
Cyclophosphamide
Given IV.
Cytarabine
Given IV or by subcutaneous injection (SQ).
Mercaptopurine
Given PO.
Dasatinib
Given PO.
Methotrexate
Given IV.
Blinatumomab
Given IV.
Ruxolitinib
Given PO.
Bortezomib
Given IV or subcutaneously (SQ).
Dexamethasone
Given PO.
Doxorubicin
Given IV.
Etoposide
Given IV.
Clofarabine
Given IV.
Vorinostat
Given PO.
Idarubicin
Given IV.
Nelarabine
Given IV.
Thioguanine
Participants with mercaptopurine-related pancreatitis. Given PO.
Asparaginase Erwinia chrysanthemi (recombinant)-rywn
To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
Calaspargase Pegol
To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
The Royal Children's Hospital Melbourne, Parkville
St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte
St. Jude Children's Research Hospital, Memphis
Children's Hospital of Michigan, Detroit
Children's Hospital of Illinois at OSF-Saint Francis Medical Center (St. Jude Midwest Affiliate - Peoria), Peoria
Cook Children's Medical Center, Fort Worth
Rady Children's Hospital San Diego, San Diego
Lucile Packard Children's Hospital Stanford University, Palo Alto
Collaborators (2)
Incyte Corporation
INDUSTRY
Amgen
INDUSTRY
Servier
INDUSTRY
St. Jude Children's Research Hospital
OTHER